Jaguar Health Past Earnings Performance
Past criteria checks 0/6
Jaguar Health has been growing earnings at an average annual rate of 1.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 12.9% per year.
Key information
1.8%
Earnings growth rate
96.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 12.9% |
Return on equity | -245.9% |
Net Margin | -360.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Revenue & Expenses Breakdown
How Jaguar Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 10 | -38 | 23 | 15 |
30 Jun 24 | 10 | -36 | 22 | 18 |
31 Mar 24 | 10 | -38 | 22 | 18 |
31 Dec 23 | 10 | -41 | 23 | 19 |
30 Sep 23 | 11 | -40 | 22 | 19 |
30 Jun 23 | 11 | -44 | 24 | 19 |
31 Mar 23 | 11 | -42 | 24 | 17 |
31 Dec 22 | 12 | -47 | 27 | 18 |
30 Sep 22 | 11 | -54 | 29 | 19 |
30 Jun 22 | 8 | -54 | 29 | 16 |
31 Mar 22 | 6 | -59 | 29 | 18 |
31 Dec 21 | 4 | -53 | 26 | 15 |
30 Sep 21 | 5 | -50 | 23 | 12 |
30 Jun 21 | 7 | -46 | 23 | 10 |
31 Mar 21 | 10 | -42 | 21 | 7 |
31 Dec 20 | 9 | -39 | 20 | 6 |
30 Sep 20 | 8 | -35 | 21 | 6 |
30 Jun 20 | 7 | -39 | 20 | 6 |
31 Mar 20 | 5 | -45 | 20 | 6 |
31 Dec 19 | 6 | -45 | 20 | 6 |
30 Sep 19 | 6 | -48 | 21 | 4 |
30 Jun 19 | 6 | -43 | 22 | 3 |
31 Mar 19 | 5 | -34 | 22 | 1 |
31 Dec 18 | 4 | -32 | 22 | 0 |
30 Sep 18 | 4 | -41 | 21 | 0 |
30 Jun 18 | 4 | -30 | 16 | 0 |
31 Mar 18 | 4 | -24 | 13 | 0 |
31 Dec 17 | 4 | -22 | 11 | 0 |
30 Sep 17 | 3 | -5 | 8 | 0 |
30 Jun 17 | 2 | -14 | 9 | 0 |
31 Mar 17 | 1 | -17 | 9 | 0 |
31 Dec 16 | 0 | -15 | 6 | 0 |
31 Dec 15 | 0 | 5 | 3 | 2 |
Quality Earnings: JAGX is currently unprofitable.
Growing Profit Margin: JAGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JAGX is unprofitable, but has reduced losses over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare JAGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JAGX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: JAGX has a negative Return on Equity (-245.95%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 08:12 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jaguar Health, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Robert LeBoyer | Aegis Capital Corporation |
Louise Chen | Cantor Fitzgerald & Co. |
Vernon Bernardino | H.C. Wainwright & Co. |